Cardiometabolic Risk, Obesity and Cardiovascular Disease in People With Spinal Cord Injury
| Status: | Completed |
|---|---|
| Conditions: | Obesity Weight Loss, Peripheral Vascular Disease, Hospital, Orthopedic |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Endocrinology, Orthopedics / Podiatry, Other |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 4/21/2016 |
| Start Date: | March 2010 |
| End Date: | December 2015 |
The purpose of this study is to develop and field-test new tools for diagnosis and hazard
assessment of cardiometabolic risk (CMR) in people with chronic spinal cord injury (SCI) and
to advance the evidence base with much needed information on CMR and cardiovascular disease
(CVD) burden in people with SCI. These data can be used to develop screening guidelines for
early identification and prevention of CMR in SCI, as well as targeted approaches to primary
disease management.
assessment of cardiometabolic risk (CMR) in people with chronic spinal cord injury (SCI) and
to advance the evidence base with much needed information on CMR and cardiovascular disease
(CVD) burden in people with SCI. These data can be used to develop screening guidelines for
early identification and prevention of CMR in SCI, as well as targeted approaches to primary
disease management.
Unlike current assessments utilizing lipid scores, the new system will be anchored in more
reliable measurements of cardiovascular disease (CVD) burden using contemporary surrogate
end points of coronary artery calcium (CAC) score, coronary CT angiography and carotid
intima media thickness (CIMT). By the end of the 5-year funding cycle we will develop an
updatable web-based cardiometabolic risk assessment tool (RISK) that will allow clinicians
and SCI consumers to quantify risk for a cardiovascular sentinel event (stroke, non-fatal
heart attack, or death) and will also provide a body mass index (BMI) table adjusted for
SCI.
Specific Aims:
1. Examine the relationships among surrogates of cardiovascular disease burden in persons
with SCI and established cardiometabolic risks.
2. Identify significant predictors of cardiometabolic risk (CMR) that are unique to
persons with specific levels of SCI.
3. Develop and validate SCI CMR assessment tool (RISK) based on cardiometabolic risk
scores.
4. Develop and validate an adjusted BMI table for SCI.
reliable measurements of cardiovascular disease (CVD) burden using contemporary surrogate
end points of coronary artery calcium (CAC) score, coronary CT angiography and carotid
intima media thickness (CIMT). By the end of the 5-year funding cycle we will develop an
updatable web-based cardiometabolic risk assessment tool (RISK) that will allow clinicians
and SCI consumers to quantify risk for a cardiovascular sentinel event (stroke, non-fatal
heart attack, or death) and will also provide a body mass index (BMI) table adjusted for
SCI.
Specific Aims:
1. Examine the relationships among surrogates of cardiovascular disease burden in persons
with SCI and established cardiometabolic risks.
2. Identify significant predictors of cardiometabolic risk (CMR) that are unique to
persons with specific levels of SCI.
3. Develop and validate SCI CMR assessment tool (RISK) based on cardiometabolic risk
scores.
4. Develop and validate an adjusted BMI table for SCI.
Inclusion Criteria:
- traumatic spinal cord injury between C4 and T12
- have a motor complete injury as classified as American Spinal Injury Association
Impairment Scale (AIS) grade A or B
- injury for more than 1 year
- no known history of traumatic brain injury, cardiovascular disease or diabetes
- not currently taking any medications to treat cardiovascular disease or diabetes
- have multiple (i.e., 2+) of the following cardiometabolic risk factors:
1. fasting triglyceride > 150 mg/dL
2. HDLC < 40 mg/dL
3. hs-CRP > 3.0
4. body fat (by DEXA) >25% for males and 33% for females
Exclusion Criteria:
- history of allergy or hypersensitivity to fish and/or nuts
- undergoing anticoagulant therapies
We found this trial at
1
site
Click here to add this to my saved trials
